In the Journals

Anti-IL1 linked with reduced attacks, proteinuria in patients with familial Mediterranean fever

Use of anti-interleukin-1 for treatment of patients with colchicine-resistant familial Mediterranean fever effectively controlled attacks and decreased proteinuria, according to results.

Researchers reviewed the medical records of 172 patients with familial Mediterranean fever treated with anti-IL1 for at least 6 months. Researchers noted 84% of patients had colchicine-resistant disease and 12% of patients had amyloidosis.

Results showed a significant reduction in the frequency of yearly attacks during a mean 19.6 months of treatment. Researchers found 42.1% of patients with colchicine-resistant familial Mediterranean fever remained attack free. Researchers also noted a significant reduction in serum levels of C-reactive protein, erythrocyte sedimentation rate and 24-hour urinary protein excretion. Of 143 patients with sufficient data, 17% experienced an adverse event. – by Casey Tingle

Disclosure s : The researchers report no relevant financial disclosures.

Use of anti-interleukin-1 for treatment of patients with colchicine-resistant familial Mediterranean fever effectively controlled attacks and decreased proteinuria, according to results.

Researchers reviewed the medical records of 172 patients with familial Mediterranean fever treated with anti-IL1 for at least 6 months. Researchers noted 84% of patients had colchicine-resistant disease and 12% of patients had amyloidosis.

Results showed a significant reduction in the frequency of yearly attacks during a mean 19.6 months of treatment. Researchers found 42.1% of patients with colchicine-resistant familial Mediterranean fever remained attack free. Researchers also noted a significant reduction in serum levels of C-reactive protein, erythrocyte sedimentation rate and 24-hour urinary protein excretion. Of 143 patients with sufficient data, 17% experienced an adverse event. – by Casey Tingle

Disclosure s : The researchers report no relevant financial disclosures.